Rehospitalization for Heart Failure Problems and Perspectives

被引:550
作者
Gheorghiade, Mihai [1 ]
Vaduganathan, Muthiah [2 ]
Fonarow, Gregg C. [3 ]
Bonow, Robert O. [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA
[3] Ronald Reagan UCLA Med Ctr, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA USA
基金
美国医疗保健研究与质量局;
关键词
heart failure; outcomes; readmission; INITIATE LIFESAVING TREATMENT; PRESERVED EJECTION FRACTION; FOLLOW-UP; CLINICAL CHARACTERISTICS; MEDICARE BENEFICIARIES; READMISSION RATES; VASOPRESSIN ANTAGONISM; HOSPITALIZED-PATIENTS; 30-DAY READMISSION; ORGANIZED PROGRAM;
D O I
10.1016/j.jacc.2012.09.038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
With a prevalence of 5.8 million in the United States alone, heart failure (HF) is associated with high morbidity, mortality, and healthcare expenditures. Close to 1 million hospitalizations for heart failure (HHF) occur annually, accounting for over 6.5 million hospital days and a substantial portion of the estimated $37.2 billion that is spent each year on HF in the United States. Although some progress has been made in reducing mortality in patients hospitalized with HF, rates of rehospitalization continue to rise, and approach 30% within 60 to 90 days of discharge. Approximately half of HHF patients have preserved or relatively preserved ejection fraction (EF). Their post-discharge event rate is similar to those with reduced EF. HF readmission is increasingly being used as a quality metric, a basis for hospital reimbursement, and an outcome measure in HF clinical trials. In order to effectively prevent HF readmissions and improve overall outcomes, it is important to have a complete and longitudinal characterization of HHF patients. This paper highlights management strategies that when properly implemented may help reduce HF rehospitalizations and include adopting a mechanistic approach to cardiac abnormalities, treating noncardiac comorbidities, increasing utilization of evidence-based therapies, and improving care transitions, monitoring, and disease management. (J Am Coll Cardiol 2013;61:391-403) (C) 2013 by the American College of Cardiology Foundation
引用
收藏
页码:391 / 403
页数:13
相关论文
共 77 条
[1]   Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial [J].
Abraham, William T. ;
Adamson, Philip B. ;
Bourge, Robert C. ;
Aaron, Mark F. ;
Costanzo, Maria Rosa ;
Stevenson, Lynne W. ;
Strickland, Warren ;
Neelagaru, Suresh ;
Raval, Nirav ;
Krueger, Steven ;
Weiner, Stanislav ;
Shavelle, David ;
Jeffries, Bradley ;
Yadav, Jay S. .
LANCET, 2011, 377 (9766) :658-666
[2]   Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000, cases in the Acute Decompensated Heart Failure National Registry (ADHERE) [J].
Adams, KF ;
Fonarow, GC ;
Emerman, CL ;
LeJemtel, TH ;
Costanzo, MR ;
Abraham, WT ;
Berkowitz, RL ;
Galvao, M ;
Horton, DP .
AMERICAN HEART JOURNAL, 2005, 149 (02) :209-216
[3]   Ongoing right ventricular hemodynarnics in heart failure -: Clinical value of measurements derived from an implantable monitoring system [J].
Adamson, PB ;
Magalski, A ;
Braunschweig, F ;
Böhm, M ;
Reynolds, D ;
Steinhaus, D ;
Luby, A ;
Linde, C ;
Ryden, L ;
Cremers, B ;
Takle, T ;
Bennett, T .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (04) :565-571
[4]   Effects of digoxin on morbidity and mortality in diastolic heart failure: The ancillary Digitalis Investigation Group trial [J].
Ahmed, Ali ;
Rich, Michael W. ;
Fleg, Jerome L. ;
Zile, Michael R. ;
Young, James B. ;
Kitzman, Dalane W. ;
Love, Thomas E. ;
Aronow, Wilbert S. ;
Adams, Kirkwood F., Jr. ;
Gheorghiade, Mihai .
CIRCULATION, 2006, 114 (05) :397-403
[5]  
Albaghdadi Mazen, 2011, Eur Heart J, V32, P2626, DOI 10.1093/eurheartj/ehr170
[6]   Use of Aldosterone Antagonists in Heart Failure [J].
Albert, Nancy M. ;
Yancy, Clyde W. ;
Liang, Li ;
Zhao, Xin ;
Hernandez, Adrian F. ;
Peterson, Eric D. ;
Cannon, Christopher P. ;
Fonarow, Gregg C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (15) :1658-1665
[7]   Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing β-blocker therapy [J].
Bello, D ;
Shah, DJ ;
Farah, GM ;
Di Luzio, S ;
Parker, M ;
Johnson, MR ;
Cotts, WG ;
Klocke, FJ ;
Bonow, RO ;
Judd, RM ;
Gheorghiade, M ;
Kim, RJ .
CIRCULATION, 2003, 108 (16) :1945-1953
[8]   Outcome of heart failure with preserved ejection fraction in a population-based study [J].
Bhatia, R. Sacha ;
Tu, Jack V. ;
Lee, Douglas S. ;
Austin, Peter C. ;
Fang, Jiming ;
Haouzi, Annick ;
Gong, Yanyan ;
Liu, Peter P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (03) :260-269
[9]   Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure Results From the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) Program [J].
Blair, John E. A. ;
Zannad, Faiez ;
Konstam, Marvin A. ;
Cook, Thomas ;
Traver, Brian ;
Burnett, John C., Jr. ;
Grinfeld, Liliana ;
Krasa, Holly ;
Maggioni, Aldo P. ;
Orlandi, Cesare ;
Swedberg, Karl ;
Udelson, James E. ;
Zimmer, Christopher ;
Gheorghiade, Mihai .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (20) :1640-1648
[10]   Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial [J].
Blair, John E. A. ;
Pang, Peter S. ;
Schrier, Robert W. ;
Metra, Marco ;
Traver, Brian ;
Cook, Thomas ;
Campia, Umberto ;
Ambrosy, Andrew ;
Burnett, John C., Jr. ;
Grinfeld, Liliana ;
Maggioni, Aldo P. ;
Swedberg, Karl ;
Udelson, James E. ;
Zannad, Faiez ;
Konstam, Marvin A. ;
Gheorghiade, Mihai .
EUROPEAN HEART JOURNAL, 2011, 32 (20) :2563-2572